|
US4327725A
(en)
|
1980-11-25 |
1982-05-04 |
Alza Corporation |
Osmotic device with hydrogel driving member
|
|
US4624848A
(en)
|
1984-05-10 |
1986-11-25 |
Ciba-Geigy Corporation |
Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
|
|
US4968509A
(en)
|
1987-07-27 |
1990-11-06 |
Mcneilab, Inc. |
Oral sustained release acetaminophen formulation and process
|
|
IL92966A
(en)
|
1989-01-12 |
1995-07-31 |
Pfizer |
Dispensing devices powered by hydrogel
|
|
KR0182801B1
(ko)
|
1991-04-16 |
1999-05-01 |
아만 히데아키 |
고체 분산체의 제조방법
|
|
CZ282760B6
(cs)
|
1991-11-22 |
1997-09-17 |
Procter And Gamble Pharmaceuticals, Inc. |
Risedronátové prostředky se zpožděným uvolňováním
|
|
US5461140A
(en)
|
1992-04-30 |
1995-10-24 |
Pharmaceutical Delivery Systems |
Bioerodible polymers for solid controlled release pharmaceutical compositions
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
DE69332291T2
(de)
|
1992-10-16 |
2003-07-31 |
Nippon Shinyaku Co., Ltd. |
Verfahren zur herstellung von wachsmatrizes
|
|
US5686105A
(en)
|
1993-10-19 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
|
JPH11505258A
(ja)
|
1995-05-17 |
1999-05-18 |
セダーシナイ メディカル センター |
小腸における消化および吸収を改善させる脂肪酸を含む組成物
|
|
JP3498456B2
(ja)
|
1995-12-11 |
2004-02-16 |
Ｊｓｒ株式会社 |
液晶表示素子
|
|
BR9911365A
(pt)
|
1998-06-19 |
2001-03-13 |
Pfizer Prod Inc |
Compostos pirrolo[2,3-d]pirimidina
|
|
US6395300B1
(en)
|
1999-05-27 |
2002-05-28 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
|
KR20020060160A
(ko)
|
1999-08-12 |
2002-07-16 |
파마시아 이탈리아 에스.피.에이. |
3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도
|
|
IL154016A0
(en)
|
2000-08-31 |
2003-07-31 |
Pfizer Prod Inc |
Pyrazole derivatives and their use as protein kinase inhibitors
|
|
US20050209297A1
(en)
|
2000-08-31 |
2005-09-22 |
Pfizer Inc |
Pyrazole derivatives
|
|
AU2002215053A1
(en)
|
2000-11-27 |
2002-06-24 |
Pharmacia Italia S.P.A. |
Phenylacetamido- pyrazole derivatives and their use as antitumor agents
|
|
US6465014B1
(en)
|
2001-03-21 |
2002-10-15 |
Isp Investments Inc. |
pH-dependent sustained release, drug-delivery composition
|
|
CN1300116C
(zh)
|
2001-04-16 |
2007-02-14 |
卫材株式会社 |
1h－吲唑化合物
|
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
FR2831536A1
(fr)
|
2001-10-26 |
2003-05-02 |
Aventis Pharma Sa |
Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
|
|
JP5039268B2
(ja)
|
2001-10-26 |
2012-10-03 |
アベンティス・ファーマスーティカルズ・インコーポレイテツド |
ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
|
|
DE10219294A1
(de)
|
2002-04-25 |
2003-11-13 |
Schering Ag |
Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
|
|
KR20120032574A
(ko)
|
2002-10-03 |
2012-04-05 |
탈자진 인코포레이티드 |
혈관항상성 유지제 및 그의 사용 방법
|
|
US20050282814A1
(en)
|
2002-10-03 |
2005-12-22 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
|
US7687506B2
(en)
|
2003-04-11 |
2010-03-30 |
The Regents Of The University Of California |
Selective serine/threonine kinase inhibitors
|
|
JP2006522750A
(ja)
|
2003-04-11 |
2006-10-05 |
ノボ ノルディスク アクティーゼルスカブ |
代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
|
|
ATE467616T1
(de)
|
2003-04-11 |
2010-05-15 |
High Point Pharmaceuticals Llc |
Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
|
|
EP1615667A2
(en)
|
2003-04-11 |
2006-01-18 |
Novo Nordisk A/S |
Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
|
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
|
WO2005030206A1
(en)
|
2003-09-24 |
2005-04-07 |
Imclone Systems Incorporated |
Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
|
|
WO2005042495A1
(en)
|
2003-10-21 |
2005-05-12 |
Imclone Systems Incorporated |
(benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity
|
|
MXPA06004657A
(es)
|
2003-10-28 |
2006-06-27 |
Pharmacia Corp |
Combinaciones que comprenden un inhibidor de hsp90 y un inhibidor de fosfodiesterasa para tratar o prevenir la neoplasia.
|
|
TWI372624B
(en)
|
2004-03-30 |
2012-09-21 |
Vertex Pharma |
Azaindoles useful as inhibitors of jak and other protein kinases
|
|
KR20070002081A
(ko)
|
2004-04-02 |
2007-01-04 |
버텍스 파마슈티칼스 인코포레이티드 |
Ｒｏｃｋ 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌
|
|
UY28931A1
(es)
|
2004-06-03 |
2005-12-30 |
Bayer Pharmaceuticals Corp |
Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
|
|
DE102004048877A1
(de)
|
2004-10-07 |
2006-04-13 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
PI3-Kinasen
|
|
KR20070064660A
(ko)
|
2004-10-07 |
2007-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
Ｐｉ３ 키나제
|
|
EP1814883A1
(en)
|
2004-11-22 |
2007-08-08 |
Vertex Pharmaceuticals Incorporated |
Bicyclic inhibitors or rho kinase
|
|
FR2878849B1
(fr)
|
2004-12-06 |
2008-09-12 |
Aventis Pharma Sa |
Indoles substitues, compositions les contenant, procede de fabrication et utilisation
|
|
DOP2006000051A
(es)
|
2005-02-24 |
2006-08-31 |
Lilly Co Eli |
Inhibidores de vegf-r2 y métodos
|
|
GB0507575D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
JP2008540395A
(ja)
|
2005-05-03 |
2008-11-20 |
ファイザー・インク |
アミドレソルシノール化合物
|
|
FR2885904B1
(fr)
|
2005-05-19 |
2007-07-06 |
Aventis Pharma Sa |
Nouveaux derives du fluorene, compositions les contenant et utilisation
|
|
EP1899299B1
(en)
|
2005-06-27 |
2010-10-20 |
Bristol-Myers Squibb Company |
C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
|
EP1910385B1
(en)
|
2005-08-04 |
2013-07-24 |
Sirtris Pharmaceuticals, Inc. |
Benzothiazoles and thiazolopyridines as sirtuin modulators
|
|
DE102005037499A1
(de)
|
2005-08-09 |
2007-02-15 |
Merck Patent Gmbh |
Pyrazolderivate
|
|
EP1955077B1
(en)
|
2005-12-02 |
2012-06-13 |
Sirtris Pharmaceuticals, Inc. |
Mass spectrometry assays for acetyltransferase/deacetylase activity
|
|
KR101461680B1
(ko)
|
2005-12-02 |
2014-11-19 |
바이엘 헬스케어 엘엘씨 |
과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
|
|
MX2008010187A
(es)
|
2006-02-10 |
2008-10-31 |
Summit Corp Plc |
Tratamiento de distrofia muscular de duchenne.
|
|
JP5255559B2
(ja)
|
2006-03-31 |
2013-08-07 |
アボット・ラボラトリーズ |
インダゾール化合物
|
|
EP2121626A1
(en)
|
2006-12-15 |
2009-11-25 |
Pfizer Products Inc. |
Benzimidazole derivatives
|
|
JP2010535708A
(ja)
|
2007-08-03 |
2010-11-25 |
ビオマリン アイジーエー リミテッド |
デュシェンヌ型筋ジストロフィーの治療のための薬物併用
|
|
RU2364597C1
(ru)
|
2007-12-14 |
2009-08-20 |
Андрей Александрович Иващенко |
ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
|
|
CA2709784A1
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
US20100168084A1
(en)
|
2008-05-08 |
2010-07-01 |
Huber L Julie |
Therapeutic compounds and related methods of use
|
|
MX2011000834A
(es)
|
2008-07-23 |
2011-04-05 |
Vertex Pharma |
Inhibidores de pirazolopiridin cinasa.
|
|
US8486936B2
(en)
|
2009-05-05 |
2013-07-16 |
AllaChem, LLC |
Antagonist of smoothened
|
|
CA2772790C
(en)
|
2009-09-04 |
2017-06-27 |
Benjamin Bader |
Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
|
|
GB201009853D0
(en)
|
2010-06-11 |
2010-07-21 |
Chroma Therapeutics Ltd |
HSP90 inhibitors
|
|
BR112013025142A2
(pt)
|
2011-04-01 |
2019-09-24 |
Univ Utah Res Found |
análogos de 3-(1h-benzo{d}imidazol-2-il)-1h-indazol substituído como inibidores da cinase pdk1
|
|
JP2014166961A
(ja)
|
2011-06-20 |
2014-09-11 |
Dainippon Sumitomo Pharma Co Ltd |
新規インダゾール誘導体
|
|
CN102266341A
(zh)
|
2011-06-20 |
2011-12-07 |
广州市第十二人民医院 |
嗓唑并嘧啶类化合物在制备治疗肺癌药物中的应用
|
|
US9745304B2
(en)
|
2013-01-30 |
2017-08-29 |
Bayer Pharma Aktiengesellschaft |
Amidoimidazopyridazines as MKNK-1 kinase inhibitors
|
|
KR20140125117A
(ko)
|
2013-04-18 |
2014-10-28 |
한국화학연구원 |
카르바닐리드 유도체를 유효성분으로 포함하는 이상증식혈관 질환의 예방 또는 치료용 조성물
|
|
WO2015000959A1
(en)
|
2013-07-03 |
2015-01-08 |
Norwegian University Of Science And Technology (Ntnu) |
4-amino-6-aryl[2,3-d]pyrimidines for the inhibition of egfr tyrosine kinase
|
|
GB201316824D0
(en)
|
2013-09-23 |
2013-11-06 |
R & D Vernalis Ltd |
New Chemical Entities
|
|
JP2015183128A
(ja)
|
2014-03-25 |
2015-10-22 |
東洋インキＳｃホールディングス株式会社 |
波長変換性樹脂組成物及び太陽電池封止材
|
|
EP2924039A1
(en)
|
2014-03-27 |
2015-09-30 |
Universität Zürich |
2-Amino-1-phenyl-pyrrolo[3,2-b]quinoxaline-3-carboxamide derivates
|
|
CN110526912B
(zh)
|
2014-06-19 |
2023-02-14 |
武田药品工业株式会社 |
用于激酶抑制的杂芳基化合物
|
|
GB201417561D0
(en)
|
2014-10-03 |
2014-11-19 |
Redx Pharma Ltd |
Compounds
|
|
AR103297A1
(es)
|
2014-12-30 |
2017-05-03 |
Forma Therapeutics Inc |
Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
|
|
WO2016148114A1
(ja)
|
2015-03-13 |
2016-09-22 |
国立大学法人北海道大学 |
酸化ストレス誘導神経細胞死抑制化合物
|
|
US10787444B2
(en)
|
2015-06-05 |
2020-09-29 |
Syros Pharmaceuticals, Inc. |
Compounds for the modulation of myc activity
|
|
WO2016202758A1
(en)
|
2015-06-18 |
2016-12-22 |
Bayer Pharma Aktiengesellschaft |
Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
|
|
WO2017075367A1
(en)
|
2015-10-28 |
2017-05-04 |
Northwestern University |
Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
|
|
US10851082B2
(en)
|
2015-10-28 |
2020-12-01 |
Northwestern University |
Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
|
|
CN107176951A
(zh)
|
2016-03-11 |
2017-09-19 |
恩瑞生物医药科技（上海）有限公司 |
一种脲类化合物、其制备方法及其医药用途
|
|
CN109152784B
(zh)
|
2016-03-16 |
2021-12-28 |
库拉肿瘤学公司 |
经取代的menin-mll抑制剂及使用方法
|
|
CN109640987B
(zh)
|
2016-03-16 |
2022-12-02 |
库拉肿瘤学公司 |
Menin-mll的桥联双环抑制剂及使用方法
|
|
WO2017161280A1
(en)
|
2016-03-18 |
2017-09-21 |
Kyocera Corporation |
System and method for dual-coding for dual-hops channels
|
|
WO2017192543A1
(en)
|
2016-05-02 |
2017-11-09 |
Regents Of The University Of Michigan |
Piperidines as menin inhibitors
|
|
CN105997965B
(zh)
|
2016-05-25 |
2018-05-08 |
山东大学 |
小分子化合物作为佐剂在制备抗真菌药物中的应用
|
|
EP3805215A1
(en)
|
2016-06-10 |
2021-04-14 |
Vitae Pharmaceuticals, LLC |
Inhibitors of the menin-mll interaction
|
|
WO2018106818A1
(en)
|
2016-12-07 |
2018-06-14 |
Kura Oncology, Inc. |
Methods of promoting beta cell proliferation
|
|
US11452717B2
(en)
|
2017-01-10 |
2022-09-27 |
Sanford Burnham Prebys Medical Discovery Institute |
Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof
|
|
US11247970B2
(en)
|
2017-03-22 |
2022-02-15 |
Dana-Farber Cancer Institute, Inc. |
Selective inhibition of gluconeogenic activity
|
|
CA3058448A1
(en)
|
2017-03-31 |
2018-10-04 |
The Regents Of The University Of Michigan |
Piperidines as covalent menin inhibitors
|
|
CA3092625A1
(en)
|
2018-04-05 |
2019-10-10 |
Merck Patent Gmbh |
Heteroaryl compounds as type ii irak inhibitors and uses thereof
|
|
CN108727295B
(zh)
|
2018-06-21 |
2022-04-01 |
济南大学 |
一种2-(3-氨基苯基)-苯并噻唑衍生物及其制备方法和用途
|
|
TW202043205A
(zh)
|
2018-12-31 |
2020-12-01 |
美商拜歐米富士恩有限公司 |
Menin-mll相互作用之抑制劑
|
|
EP3906026A4
(en)
|
2018-12-31 |
2022-10-19 |
Biomea Fusion, LLC |
IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
|
|
MX2021015675A
(es)
|
2019-06-26 |
2022-02-03 |
Nurix Therapeutics Inc |
Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
|
|
US20240124467A1
(en)
|
2020-12-16 |
2024-04-18 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
|
AU2022325861A1
(en)
|
2021-08-11 |
2024-02-29 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
|
IL310717A
(en)
|
2021-08-20 |
2024-04-01 |
Biomea Fusion Inc |
Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
|